Weekly Recap | Zai Lab -7.2%, ZL-1503 data catalyst drives rebound
Weekly Review·
- Zides Laboratories experienced a 7.2% weekly decline to close at $23.19, though it rebounded mid-week following the announcement of ZL-1503 clinical data for the upcoming ACAAI meeting.
- Twelve institutional ratings generated a strong buy consensus with a target price of $33.14, representing a 42.9% upside from the current price.
- The company remains in an unprofitable stage with a PB ratio of 4.23, while future market performance will depend on the actual data release of ZL-1503 and macroeconomic updates.